<DOC>
	<DOCNO>NCT00309556</DOCNO>
	<brief_summary>Primarily , clinical investigation compare rate ( percentage ) pathological complete remission attain time final surgery follow 6 cycle epirubicin + docetaxel + capecitabine-containing chemotherapy ± trastuzumab ( HER-2 positive disease ) vs. epirubicin + docetaxel-containing chemotherapy ± trastuzumab ( HER-2 negative disease ) .</brief_summary>
	<brief_title>Randomized Neoadjuvant Study Epirubicin Docetaxel With/Without Capecitabine Early Breast Cancer</brief_title>
	<detailed_description>This study prospective , randomize , multicentre , phase III trial neoadjuvant treatment patient primary breast cancer distant metastasis . Patients stratify inclusion accord centre , clinical tumour stage ( T1 , T2 , T3 , T4a-c ) , axillary lymph node status ( positive , negative ) , menopausal status ( pre-menopausal , post-menopausal ) , histology ( invasive ductal , invasive lobular , mixed ) , hormone-receptor status ( positive [ ER+/PR+ , ER+/PR- , ER-/PR+ ] , negative [ ER-/PR- ] , determinable ] ) , HER-2 status ( positive , negative , determinable ) , grade ( G1/G2 , G3 , determinable ) randomly assign receive either 6 cycle neoadjuvant epirubicin , docetaxel capecitabine ± trastuzumab HER-2 positive disease 6 cycle neoadjuvant epirubicin docetaxel ± trastuzumab HER-2 positive disease .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Female patient histologically proven , corebiopsied , invasive breast cancer clinical and/or radiological Tstage ( except T4d ) Age 1870 year WHO performance status ≤ 2 No prior current neoplasm except curatively treat nonmelanoma skin cancer , situ carcinoma cervix No distant disease / secondary carcinoma judge clinically least chest Xray , liver sonography , bone scan upon randomization No medical and/or cardiologic contraindication receive anthracycline taxanecontaining chemotherapy regimen . Normal cardiac function must confirm LVEF ( echocardiography Muga scan ) . The result must 50 % institution 's ULN Results follow assessment time randomization must available : 1. chest wall CT , abdomen CT , bilateral mammography : within 4 week enrolment ; 2. laboratory requirement : within 2 week enrolment 3. hematology : neutrophil ≥ 4.0 x 109/l , platelet ≥ 150 x 109/l , haemoglobin ≥ 13 g/dl 4. hepatic function : total bilirubin &lt; 1 x ULN , ASAT ( SGOT ) ALAT ( SGPT ) &lt; 1x ULN , alkaline phosphatase &lt; 1 x ULN . In case abnormal value , liver function test repeat within 3 day study treatment . 5. renal function : creatinine ≤ 1 x ULN , 6. histology , grading , hormone receptor status , HER2/neu status Signed date informed consent start specific protocol procedure Negative pregnancy test presence childbearing potential Stage T4d / inflammatory breast cancer Pregnant lactating patient ; patient childbearing potential must implement adequate contraceptive measure study participation Preexisting motor sensory neurotoxicity severity ≥ WHO grade 2 Preoperative local treatment breast cancer ( i.e . incomplete surgery , radiotherapy ) Prior concomitant systemic antitumor therapy Other serious illness medical condition 1. congestive heart failure unstable angina pectoris , even medically control . Previous history myocardial infarction within 1 year study entry , uncontrolled hypertension highrisk uncontrolled arrythmias 2. history significant neurologic psychiatric disorder , include psychotic disorder , dementia seizure would prohibit understanding give informed consent 3. active uncontrolled infection 4. unstable peptic ulcer , unstable diabetes mellitus contraindication use corticosteroid Concurrent treatment corticosteroid except use prophylactic regimen , inhalational use , treatment acute hypersensitivity reaction , treatment nausea/vomiting chronic treatment ( initiate &gt; 6 month prior study entry ) low dose ( ≤ 20 mg methylprednisolone equivalent ) Known hypersensitivity taxanes and/or epirubicin and/or fluorouracil/capecitabine Known dihydropyrimidinedehydrogenase ( DPD ) deficit Treatment investigational drug within 30 day prior study entry Legally incapacitate and/or circumstance make unfeasible subject understand nature , mean consequence clinical study Concurrent psychiatric illness accord ICD ( alcohol addiction ) time study entry</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Epirubicin</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Herceptin</keyword>
	<keyword>Breast cancer</keyword>
</DOC>